Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders

Translational Psychiatry

Volumn 6, Issue 6, 2016, Pages

  Theoharides, T C ^a,b   Tsilioni, I ^a   Patel, A B ^a,b   Doyle, R ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CORTICOTROPIN RELEASING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 6; MACROPHAGE ACTIVATING FACTOR; NEUROTENSIN; RISPERIDONE; TUMOR NECROSIS FACTOR; AUTACOID; AUTOANTIBODY; LUTEOLIN;

ASTHMA; ATOPY; AUTISM; BLOOD BRAIN BARRIER; CELL MATURATION; CELL PROLIFERATION; CEREBROSPINAL FLUID; CONNECTOME; CORRELATIONAL STUDY; ECZEMA; ENCEPHALITIS; EPIGENETICS; FOOD ALLERGY; HUMAN; HYPOTHALAMUS; IMMUNOCOMPETENT CELL; LOW BIRTH WEIGHT; MATERNAL WELFARE; MICROGLIA; NUTRITIONAL INTOLERANCE; PATHOGENESIS; PHENOTYPE; PREMATURITY; REVIEW; TH17 CELL; BLOOD; BRAIN; CHILD; DIET THERAPY; HYPERSENSITIVITY; IMMUNOLOGY; INFLAMMATION;

AUTISM SPECTRUM DISORDER; AUTOANTIBODIES; BRAIN; CHILD; HUMANS; HYPERSENSITIVITY; INFLAMMATION; INFLAMMATION MEDIATORS; LUTEOLIN; NEUROTENSIN;

EID: 84994527318     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.77     Document Type: Review

References (214)

1. Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet 2014; 383: 896–910.
2. Volkmar FR, McPartland JC. From Kanner to DSM-5: autism as an evolving diagnostic concept. Annu Rev Clin Psychol 2014; 10: 193–212.
3. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009; 65: 591–598.
4. Geschwind DH, State MW. Gene hunting in autism spectrum disorder: on the path to precision medicine. Lancet Neurol 2015; 11: 1109–1120.
5. Willsey AJ, State MW. Autism spectrum disorders: from genes to neurobiology. Curr Opin Neurobiol 2015; 30: 92–99.
6. Kazdoba TM, Leach PT, Crawley JN. Behavioral phenotypes of genetic mouse models of autism. Genes Brain Behav 2015; 15: 7–26.
7. Ruhela RK, Prakash A, Medhi B. An urgent need for experimental animal model of autism in drug development. Ann Neurosci 2015; 22: 44–49.
8. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110: 3507–3512.
9. Tsilioni I, Dodman N, Petra AI, Taliou A, Francis K, Moon-Fanelli AA et al. Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing bull terriers with a phenotype similar to autism. Transl Psychiatry 2014; 4: e466.
10. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal InvestigatorsCenters for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 2014; 63: 1–21.
11. Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcin C et al. Global prevalence of autism and other pervasive developmental disorders. Autism Res 2012; 5: 160–179.
12. Ruggeri B, Sarkans U, Schumann G, Persico AM. Biomarkers in autism spectrum disorder: the old and the new. Psychopharmacology (Berl) 2014; 231: 1201–1216.
13. Theoharides TC, Doyle R, Francis K, Conti P, Kalogeromitros D. Novel therapeutic targets for autism. Trends Pharmacol Sci 2008; 29: 375–382.
14. Bauman ML. Medical comorbidities in autism: challenges to diagnosis and treatment. Neurotherapeutics 2010; 7: 320–327.
15. Olfson M, Druss BG, Marcus SC. Trends in mental health care among children and adolescents. N Engl J Med 2015; 372: 2029–2038.
16. Leigh JP, Du J. Brief report: forecasting the economic burden of autism in 2015 and 2025 in the United States. J Autism Dev Disord 2015; 12: 4135–4139.
17. Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry 2012; 17: 389–401.
18. Angelidou A, Asadi S, Alysandratos KD, Karagkouni A, Kourembanas S, Theo-harides TC. Perinatal stress, brain inflammation and risk of autism-Review and proposal. BMC Pediatr 2012; 12: 89.
19. Herbert MR. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr Opin Neurol 2010; 23: 103–110.
20. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med 2015; 373: 163–172.
21. Grimbaldeston MA. Mast cell-MrgprB2: sensing secretagogues or a means to overreact? Immunol Cell Biol 2015; 93: 221–223.
22. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008; 8: 478–486.
23. Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B et al. Mast cells and inflammation. Biochim Biophys Acta 2012; 1822: 21–33.
24. Chang HY, Seo JH, Kim HY, Kwon JW, Kim BJ, Kim HB et al. Allergic diseases in preschoolers are associated with psychological and behavioural problems. Allergy Asthma Immunol Res 2013; 5: 315–321.
25. Theoharides TC. Is a subtype of autism an 'allergy of the brain'?. Clin Therap 2013; 35: 584–591.
26. Theoharides TC, Asadi S, Patel AB. Focal brain inflammation and autism. J Neuro-inflammation 2013; 10: 46.
27. Theoharides TC, Stewart JM, Panagiotidou S, Melamed I. Mast cells, brain inflammation and autism. Eur J Pharmacol 2015; pii S0014-2999: 00398–2.
28. Young AM, Chakrabarti B, Roberts D, Lai MC, Suckling J, Baron-Cohen S. From molecules to neural morphology: understanding neuroinflammation in autism spectrum condition. Mol Autism 2016; 7: 9.
29. Kern JK, Geier DA, Sykes LK, Geier MR. Relevance of neuroinflammation and encephalitis in autism. Front Cell Neurosci 2015; 9: 519.
30. Zuckerman KE, Hill AP, Guion K, Voltolina L, Fombonne E. Overweight and obesity: prevalence and correlates in a large clinical sample of children with autism spectrum disorder. J Autism Dev Disord 2014; 44: 1708–1719.
31. Granich J, Lin A, Hunt A, Wray J, Dass A, Whitehouse AJ. Obesity and associated factors in youth with an autism spectrum disorder. Autism 2016; pii: 1362361315616345; e-pub ahead of print.
32. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415–445.
33. Theoharides TC, Sismanopoulos N, Delivanis DA, Zhang B, Hatziagelaki EE, Kalogeromitros D. Mast cells squeeze the heart and stretch the gird: their role in atherosclerosis and obesity. Trends Pharmacol Sci 2011; 32: 534–542.
34. Liu J, Divoux A, Sun J, Zhang J, Clement K, Glickman JN et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009; 15: 940–945.
35. Taildeman J, Perez-Novo CA, Rottiers I, Ferdinande L, Waeytens A, De C. V et al. Human mast cells express leptin and leptin receptors. Histochem Cell Biol 2009; 131: 703–711.
36. Zhou Y, Yu X, Chen H, Sjoberg S, Roux J, Zhang L et al. Leptin deficiency shifts mast cells toward anti-inflammatory actions and protects mice from obesity and diabetes by polarizing M2 macrophages. Cell Metab 2015; 22: 1045–1058.
37. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic dis-ease. J Clin Invest 2011; 121: 2111–2117.
38. Ashwood P, Kwong C, Hansen R, Hertz-Picciotto I, Croen L, Krakowiak P et al. Brief report: plasma leptin levels are elevated in autism: association with early onset phenotype? J Autism Dev Disord 2007; 38: 169–175.
39. Rodriguez JI, Kern JK. Evidence of microglial activation in autism and its possible role in brain underconnectivity. Neuron Glia Biol 2011; 7: 205–213.
40. Adams-Chapman I. Neurodevelopmental outcome of the late preterm infant. Clin Perinatol 2006; 33: 947–964.
41. Volpe JJ. The encephalopathy of prematurity--brain injury and impaired brain development inextricably intertwined. Semin Pediatr Neurol 2009; 16: 167–178.
42. Johnson S, Marlow N. Preterm birth and childhood psychiatric disorders. Pediatr Res 2011; 5, Pt 2 11 R–18R.
43. Limperopoulos C, Bassan H, Sullivan NR, Soul JS, Robertson RL Jr, Moore M et al. Positive screening for autism in ex-preterm infants: prevalence and risk factors. Pediatrics 2008; 121: 758–765.
44. Kleinman JM, Robins DL, Ventola PE, Pandey J, Boorstein HC, Esser EL et al. The modified checklist for autism in toddlers: a follow-up study investigating the early detection of autism spectrum disorders. J Autism Dev Disord 2008; 38: 827–839.
45. Maimburg RD, Vaeth M. Perinatal risk factors and infantile autism. Acta Psychiatr Scand 2006; 114: 257–264.
46. Hultman CM, Sparen P, Cnattingius S. Perinatal risk factors for infantile autism. Epidemiology 2002; 13: 417–423.
47. Ronald A, Pennell CE, Whitehouse AJ. Prenatal maternal stress associated with ADHD and autistic traits in early childhood. Front Psychol 2010; 1: 223.
48. Roberts AL, Koenen KC, Lyall K, Robinson EB, Weisskopf MG. Association of autistic traits in adulthood with childhood abuse, interpersonal victimization, and posttraumatic stress. Child Abuse Negl 2015; 45: 135–142.
49. Roberts AL, Lyall K, Rich-Edwards JW, Ascherio A, Weisskopf MG. Association of maternal exposure to childhood abuse with elevated risk for autism in offspring. JAMA Psychiatry 2013; 70: 508–515.
50. Vasa RA, Mazurek MO. An update on anxiety in youth with autism spectrum disorders. Curr Opin Psychiatry 2015; 28: 83–90.
51. van Steensel FJ, Bogels SM, Perrin S. Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis. Clin Child Fam Psychol Rev 2011; 14: 302–317.
52. Rodgers J, Glod M, Connolly B, McConachie H. The relationship between anxiety and repetitive behaviours in autism spectrum disorder. J Autism Dev Disord 2012; 42: 2404–2409.
53. Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Theoharides TC. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 2006; 103: 7759–7764.
54. Lantos TA, Palkovits M, Rostene W, Berod A. Neurotensin receptors in the human amygdaloid complex. Topographical and quantitative autoradiographic study. J Chem Neuroanat 1996; 11: 209–217.
55. Najimi M, Sarrieau A, Kopp N, Chigr F. An autoradiographic study of neurotensin receptors in the human hypothalamus. Acta Histochem 2014; 116: 382–389.
56. Esposito P, Chandler N, Kandere-Grzybowska K, Basu S, Jacobson S, Connolly R et al. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 2002; 303: 1061–1066.
57. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005; 174: 7665–7675.
58. Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci 2007; 12: 1615–1628.
59. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, varez-Twose I et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2016; 137: 35–45.
60. Theoharides TC, Enakuua S, Sismanopoulos N, Papadimas E, Angelidou A, Aly-sandratos K. Stress contributes to asthma worsening through mast cell activa-tion. Ann Allergy Asthma Immunol 2012; 109: 14–19.
61. Karagkouni A, Alevizos M, Theoharides TC. Effect of stress on brain inflammation and multiple sclerosis. Autoimmun Rev 2013; 12: 947–953.
62. Lyall K, Van de Water J, Ashwood P, Hertz-Picciotto I. Asthma and allergies in children with autism spectrum disorders: results from the CHARGE study. Autism Res 2015; 8: 567–574.
63. Chen SW, Zhong XS, Jiang LN, Zheng XY, Xiong YQ, Ma SJ et al. Maternal autoimmune diseases and the risk of autism spectrum disorders in offspring: a systematic review and meta-analysis. Behav Brain Res 2015; 296: 61–69.
64. Kotey S, Ertel K, Whitcomb B. Co-occurrence of autism and asthma in a nationally-representative sample of children in the United States. J Autism Dev Disord 2014; 44: 3083–3088.
65. Theoharides TC. Autism spectrum disorders and mastocytosis. Int J Immuno-pathol Pharmacol 2009; 22: 859–865.
66. Douwes J, Brooks C, van DC, Pearce N. Importance of allergy in asthma: an epidemiologic perspective. Curr Allergy Asthma Rep 2011; 11: 434–444.
67. Vermeersch P, Bossuyt X. Prevalence and clinical significance of rare antinuclear antibody patterns. Autoimmun Rev 2013; 12: 998–1003.
68. Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 2012; 11: 754–765.
69. Gurney JG, McPheeters ML, Davis MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Arch Pediatr Adolesc Med 2006; 160: 825–830.
70. Magalhaes ES, Pinto-Mariz F, Bastos-Pinto S, Pontes AT, Prado EA, Deazevedo LC. Immune allergic response in Asperger syndrome. J Neuroimmunol 2009; 216: 108–112.
71. Bakkaloglu B, Anlar B, Anlar FY, Oktem F, Pehlivanturk B, Unal F et al. Atopic features in early childhood autism. Eur J Paediatr Neurol 2008; 12: 476–479.
72. Jyonouchi H. Autism spectrum disorders and allergy: observation from a pediatric allergy/immunology clinic. Exp Rev Clin Immunol 2010; 6: 397–411.
73. Angelidou A, Alysandratos KD, Asadi S, Zhang B, Francis K, Vasiadi M et al. Brief report: "allergic symptoms" in children with autism spectrum disorders. More than meets the eye?. J Autism Dev Disord 2011; 41: 1579–1585.
74. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 2013; 131: 428–433.
75. Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH et al. Is atopy in early childhood a risk factor for ADHD and ASD? a longitudinal study. J Psychosom Res 2014; 77: 316–321.
76. Zerbo O, Leong A, Barcellos L, Bernal P, Fireman B, Croen LA. Immune mediated conditions in autism spectrum disorders. Brain Behav Immun 2015; 46: 232–236.
77. de Theije CG, Wu J, Koelink PJ, Korte-Bouws GA, Borre Y, Kas MJ et al. Autistic-like behavioural and neurochemical changes in a mouse model of food allergy. Behav Brain Res 2014; 261: 265–274.
78. Saluja R, Metz M, Maurer M. Role and relevance of mast cells in fungal infections. Front Immunol 2012; 3: 146.
79. Urb M, Pouliot P, Gravelat FN, Olivier M, Sheppard DC. Aspergillus fumigatus induces immunoglobulin E-independent mast cell degranulation. J Infect Dis 2009; 200: 464–472.
80. Olynych TJ, Jakeman DL, Marshall JS. Fungal zymosan induces leukotriene production by human mast cells through a dectin-1-dependent mechanism. J Allergy Clin Immunol 2006; 118: 837–843.
81. Kempuraj D, Asadi S, Zhang B, Manola A, Hogan J, Peterson E et al. Mercury induces inflammatory mediator release from human mast cells. J Neuro-inflammation 2010; 7: 20.
82. McKee AS, Munks MW, MacLeod MK, Fleenor CJ, van RN, Kappler JW et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009; 183: 4403–4414.
83. Goines PE, Ashwood P. Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment. Neurotoxicol Teratol 2012; 36: 67–81.
84. Rossignol DA, Genuis SJ, Frye RE. Environmental toxicants and autism spectrum disorders: a systematic review. Transl Psychiatry 2014; 4: e360.
85. Ming X, Brimacombe M, Malek JH, Jani N, Wagner GC. Autism spectrum disorders and identified toxic land fills: co-occurrence across States. Environ Health Insights 2008; 2: 55–59.
86. Wong CT, Wais J, Crawford DA. Prenatal exposure to common environmental factors affects brain lipids and increases risk of developing autism spectrum disorders. Eur J Neurosci 2015; 42: 2742–2760.
87. Heilbrun LP, Palmer RF, Jaen CR, Svoboda MD, Miller CS, Perkins J. Maternal chemical and drug intolerances: potential risk factors for autism and attention deficit hyperactivity disorder (ADHD). J Am Board Fam Med 2015; 28: 461–470.
88. Jedrychowski W, Maugeri U, Perera F, Stigter L, Jankowski J, Butscher M et al. Cognitive function of 6-year old children exposed to mold-contaminated homes in early postnatal period. Prospective birth cohort study in Poland. Physiol Behav 2011; 104: 989–995.
89. Empting LD. Neurologic and neuropsychiatric syndrome features of mold and mycotoxin exposure. Toxicol Ind Health 2009; 25: 577–581.
90. Bernard S, Enayati A, Roger H, Binstock T, Redwood L. The role of mercury in the pathogenesis of autism. Mol Psychiatry 2002; 7 (Suppl 2): S42–S43.
91. Geier DA, Kern JK, King PG, Sykes LK, Geier MR. Hair toxic metal concentrations and autism spectrum disorder severity in young children. Int J Environ Res Public Health 2012; 9: 4486–4497.
92. Tomljenovic L, Shaw CA. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? J Inorg Biochem 2011; 105: 1489–1499.
93. Kumar V, Bal A, Gill KD. Aluminium-induced oxidative DNA damage recognition and cell-cycle disruption in different regions of rat brain. Toxicology 2009; 264: 137–144.
94. Sood PK, Nahar U, Nehru B. Stress proteins and glial cell functions during chronic aluminium exposures: protective role of curcumin. Neurochem Res 2012; 37: 639–646.
95. Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel CKobiyama K et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011; 17: 996–1002.
96. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W et al. Circulating mito-chondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464: 104–107.
97. Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol 2010; 40: 1843–1851.
98. Abraham SN St, John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010; 10: 440–452.
99. Sandig H, Bulfone-Paus S. TLR signaling in mast cells: common and unique features. Front Immunol 2012; 3: 185.
100. Zhang B, Asadi S, Weng Z, Sismanopoulos N, Theoharides TC. Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One 2012; 7: e49767.
101. Asadi S, Theoharides TC. Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin. J Neuroinflammation 2012; 9: 85.
102. Theoharides TC, Asadi S, Panagiotidou S, Weng Z. The "missing link" in auto-immunity and autism: Extracellular mitochondrial components secreted from activated live mast cells. Autoimmun Rev 2013; 12: 1136–1142.
103. Lauritzen KH, Moldestad O, Eide L, Carlsen H, Nesse G, Storm JF et al. Mito-chondrial DNA toxicity in forebrain neurons causes apoptosis, neurodegenera-tion, and impaired behavior. Mol Cell Biol 2010; 30: 1357–1367.
104. Zhang B, Angelidou A, Alysandratos KD, Vasiadi M, Francis K, Asadi S et al. Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. J Neuroinflammation 2010; 7: 80.
105. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry 2012; 17: 290–314.
106. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008; 454: 445–454.
107. Hagberg H, Gressens P, Mallard C. Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. Ann Neurol 2012; 71: 444–457.
108. Jones KA, Thomsen C. The role of the innate immune system in psychiatric disorders. Mol Cell Neurosci 2013; 53: 52–62.
109. Chavarria A, Alcocer-Varela J. Is damage in central nervous system due to inflammation? Autoimmun Rev 2004; 3: 251–260.
110. Le Belle JE, Sperry J, Ngo A, Ghochani Y, Laks DR, Lopez-Aranda M et al. Maternal inflammation contributes to brain overgrowth and autism-associated behaviors through altered redox signaling in stem and progenitor cells. Stem Cell Rep 2014; 3: 725–734.
111. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 2012; 26: 383–392.
112. Estes ML, McAllister AK. Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nat Rev Neurosci 2015; 16: 469–486.
113. Bauman MD, Iosif AM, Smith SE, Bregere C, Amaral DG, Patterson PH. Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring. Biol Psychiatry 2014; 75: 332–341.
114. Gesundheit B, Rosenzweig JP, Naor D, Lerer B, Zachor DA, Prochazka V et al. Immunological and autoimmune considerations of Autism Spectrum Disorders. J Autoimmun 2013; 44: 1–7.
115. Braunschweig D, Van de Water J. Maternal autoantibodies in autism. Arch Neurol 2012; 69: 693–699.
116. Zimmerman AW, Connors SL, Matteson KJ, Lee LC, Singer HS, Castaneda JA et al. Maternal antibrain antibodies in autism. Brain Behav Immun 2007; 21: 351–357.
117. Rossi CC, Van de Water J, Rogers SJ, Amaral DG. Detection of plasma auto-antibodies to brain tissue in young children with and without autism spectrum disorders. Brain Behav Immun 2011; 25: 1123–1135.
118. Ribatti D. The crucial role of mast cells in blood-brain barrier alterations. Exp Cell Res 2015; 338: 119–125.
119. Mostafa GA, Al-Ayadhi LY. The possible relationship between allergic manifestations and elevated serum levels of brain specific auto-antibodies in autistic children. J Neuroimmunol 2013; 261: 77–81.
120. Zimmerman AW, Jyonouchi H, Comi AM, Connors SL, Milstien S, Varsou A et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 2005; 33: 195–201.
121. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009; 207: 111–116.
122. Tsilioni I, Taliou A, Francis K, Theoharides TC. Children with Autism Spectrum Disorders, who improved with a luteolin containing dietary formulation, show reduced serum levels of TNF and IL-6. Transl Psychiatry 2015; 5: e647.
123. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 2011; 25: 40–45.
124. Krakowiak P, Goines PE, Tancredi DJ, Ashwood P, Hansen RL, Hertz-Picciotto I et al. Neonatal cytokine profiles asAnchorsociated with autism spectrum dis-order. Biol Psychiatry 2015; S0006-3223(15)00655-1.
125. Zerbo O, Yoshida C, Grether JK, Van de Water J, Ashwood P, Delorenze GN et al. Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder: the Early Markers for Autism (EMA) study: a case-control study. J Neuroinflammation 2014; 11: 113.
126. Goines PE, Croen LA, Braunschweig D, Yoshida CK, Grether J, Hansen R et al. Increased midgestational IFN-gamma, IL-4 and IL-5 in women bearing a child with autism: a case-control study. Mol Autism 2011; 2: 13.
127. Nakae S, Suto H, Berry GJ, Galli SJ. Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. Blood 2007; 109: 3640–3648.
128. Ye CJ, Feng T, Kwon HK, Raj T, Wilson MT, Asinovski N et al. Intersection of population variation and autoimmunity genetics in human T cell activation. Science 2014; 345: 1254665.
129. Chen X, Churchill MJ, Nagar KK, Tailor YH, Chu T, Rush BS et al. IL-17 producing mast cells promote the expansion of myeloid-derived suppressor cells in a mouse allergy model of colorectal cancer. Oncotarget 2015; 6: 32966–32979.
130. Al-Ayadhi LY, Mostafa GA. Elevated serum levels of interleukin-17 A in children with autism. J Neuroinflammation 2012; 9: 158.
131. Akintunde ME, Rose M, Krakowiak P, Heuer L, Ashwood P, Hansen R et al. Increased production of IL-17 in children with autism spectrum disorders and co-morbid asthma. J Neuroimmunol 2015; 286: 33–41.
132. Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV et al. The maternal interleukin-17a pathway in mice promotes autismlike phenotypes in offspring. Science 2016; pii: aad0314.
133. Hsiao EY, McBride SW, Chow J, Mazmanian SK, Patterson PH. Modeling an autism risk factor in mice leads to permanent immune dysregulation. Proc Natl Acad Sci USA 2012; 109: 12776–12781.
134. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007; 27: 10695–10702.
135. Huang M, Pang X, Karalis K, Theoharides TC. Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. Cardiovasc Res 2003; 59: 241–249.
136. Kandere-Grzybowska K, Letourneau R, Kempuraj D, Donelan J, Poplawski S, Boucher W et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol 2003; 171: 4830–4836.
137. Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002; 128: 344–350.
138. Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 2005; 115: 216–223.
139. Mayado A, Teodosio C, Garcia-Montero AC, Matito A, Rodriguez-Caballero A, Morgado JM et al. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. Leukemia 2015; 30: 124–130.
140. Abdallah MW, Larsen N, Grove J, Norgaard-Pedersen B, Thorsen P, Mortensen EL et al. Amniotic fluid chemokines and autism spectrum disorders: an exploratory study utilizing a Danish Historic Birth Cohort. Brain Behav Immun 2012; 26: 170–176.
141. Zhang B, Weng Z, Sismanopoulos N, Asadi S, Therianou A, Alysandratos KD et al. Mitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cells. Int Arch Allergy Immunol 2012; 159: 23–32.
142. Cohly HH, Panja A. Immunological findings in autism. Int Rev Neurobiol 2005; 71: 317–341.
143. Gomez G, Ramirez CD, Rivera J, Patel M, Norozian F, Wright HV et al. TGF-beta1 inhibits mast cell FcåRI expression. J Immunol 2005; 174: 5987–5993.
144. Kashyap M, Bailey DP, Gomez G, Rivera J, Huff TF, Ryan JJ. TGF-beta1 inhibits late-stage mast cell maturation. Exp Hematol 2005; 33: 1281–1291.
145. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001; 120: 170–179.
146. Naik US, Gangadharan C, Abbagani K, Nagalla B, Dasari N, Manna SK. A study of nuclear transcription factor-kappa B in childhood autism. PLoS One 2011; 6: e19488.
147. Young AM, Campbell E, Lynch S, Suckling J, Powis SJ. Aberrant NF-kappaB expression in autism spectrum condition: a mechanism for neuroinflammation. Front Psychiatry 2011; 2: 27.
148. Ziats MN, Rennert OM. Expression profiling of autism candidate genes during human brain development implicates central immune signaling pathways. PLoS One 2011; 6: e24691.
149. Nelissen S, Lemmens E, Geurts N, Kramer P, Maurer M, Hendriks J et al. The role of mast cells in neuroinflammation. Acta Neuropathol 2013; 125: 637–650.
150. Shemer A, Erny D, Jung S, Prinz M. Microglia plasticity during health and disease: an immunological perspective. Trends Immunol 2015; 36: 614–624.
151. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P et al. Synaptic pruning by microglia is necessary for normal brain development. Science 2011; 333: 1456–1458.
152. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012; 74: 691–705.
153. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005; 57: 67–81.
154. Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J et al. Microglial activation and increased microglial density observed in the dorso-lateral prefrontal cortex in autism. Biol Psychiatry 2010; 68: 368–376.
155. Morgan JT, Barger N, Amaral DG, Schumann CM. Stereological study of amyg-dala glial populations in adolescents and adults with autism spectrum disorder. PLoS One 2014; 9: e110356.
156. Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J et al. Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat Commun 2014; 5: 5748.
157. Takano T. Role of microglia in autism: recent advances. Dev Neurosci 2015; 37: 195–202.
158. Koyama R, Ikegaya Y. Microglia in the pathogenesis of autism spectrum dis-orders. Neurosci Res 2015; 100: 1–5.
159. Wang W, Ji P, Riopelle RJ, Dow KE. Functional expression of corticotropin-releasing hormone (CRH) receptor 1 in cultured rat microglia. J Neurochem 2002; 80: 287–294.
160. Martin S, Vincent JP, Mazella J. Involvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microglia. J Neurosci 2003; 23: 1198–1205.
161. Nykjaer A, Willnow TE. Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci 2012; 35: 261–270.
162. Buttenschon HN, Demontis D, Kaas M, Elfving B, Molgaard S, Gustafsen C et al. Increased serum levels of sortilin are associated with depression and correlated with BDNF and VEGF. Transl Psychiatry 2015; 5: e677.
163. Ghanizadeh A. Targeting neurotensin as a potential novel approach for the treatment of autism. J Neuroinflammation 2010; 7: 58.
164. Patel AB, Tsilioni I, Theoharides TC. Neurotensin and corticotropin-releasing hormone synergistically activate human microglia through mammalian target of rapamycin complex 1 (mTORC1), poster # A300. American Societies for Experimental Biology: Bethesda, MD, 2015.
165. Lee dY. Roles of mTOR signaling in brain development. Exp Neurobiol 2015; 24: 177–185.
166. Lv JW, Cheng TL, Qiu ZL, Zhou WH. Role of the PTEN signaling pathway in autism spectrum disorder. Neurosci Bull 2013; 29: 773–778.
167. Tee AR, Sampson JR, Pal DK, Bateman JM. The role of mTOR signalling in neu-rogenesis, insights from tuberous sclerosis complex. Semin Cell Dev Biol 2016; 52: 12–20.
168. Kim MS, Kuehn HS, Metcalfe DD, Gilfillan AM. Activation and function of the mTORC1 pathway in mast cells. J Immunol 2008; 180: 4586–4595.
169. Dong H, Zhang W, Zeng X, Hu G, Zhang H, He S et al. Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia. Mol Neurobiol 2014; 49: 1487–1500.
170. Zhang S, Zeng X, Yang H, Hu G, He S. Mast cell tryptase induces microglia activation via protease-activated receptor 2 signaling. Cell Physiol Biochem 2012; 29: 931–940.
171. Skaper SD, Facci L, Giusti P. Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review. CNS Neurol Disord Drug Targets 2014; 13: 1654–1666.
172. Dong H, Zhang X, Wang Y, Zhou X, Qian Y, Zhang S. Suppression of brain mast cells degranulation inhibits microglial activation and central nervous system inflammation. Mol Neurobiol 2016 (in press).
173. Wong AY, Hsia Y, Chan EW, Murphy DG, Simonoff E, Buitelaar JK et al. The variation of psychopharmacological prescription rates for people with autism spectrum disorder (ASD) in 30 Countries. Autism Res 2014; 7: 543–554.
174. Spencer D, Marshall J, Post B, Kulakodlu M, Newschaffer C, Dennen T et al. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics 2013; 132: 833–840.
175. Schubart JR, Camacho F, Leslie D. Psychotropic medication trends among children and adolescents with autism spectrum disorder in the Medicaid program. Autism 2014; 18: 631–637.
176. Young NJ, Findling RL. An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Curr Opin Psychiatry 2015; 28: 91–101.
177. Lake JK, Weiss JA, Dergal J, Lunsky Y. Child, parent, and service predictors of psychotropic polypharmacy among adolescents and young adults with an autism spectrum disorder. J Child Adolesc Psychopharmacol 2014; 24: 486–493.
178. Theoharides TC, Asadi S. Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders. J Clin Psychopharmacol 2012; 32: 437–440.
179. Ecker C, Spooren W, Murphy D. Developing new pharmacotherapies for autism. J Intern Med 2013; 274: 308–320.
180. Chez MG, Guido-Estrada N. Immune therapy in autism: historical experience and future directions with immunomodulatory therapy. Neurotherapeutics 2010; 7: 293–301.
181. Liew Z, Ritz B, Virk J, Olsen J. Maternal use of acetaminophen during pregnancy and risk of autism spectrum disorders in childhood: a Danish national birth cohort study. Autism Res 2015 (in press).
182. Curran LK, Newschaffer CJ, Lee LC, Crawford SO, Johnston MV, Zimmerman AW. Behaviors associated with fever in children with autism spectrum disorders. Pediatrics 2007; 120: e1386–e1392.
183. Gupta S, Samra D, Agrawal S. Adaptive and innate immune responses in autism: rationale for therapeutic use of intravenous immunoglobulin. J Clin Immunol 2010; 30(Suppl 1): S90–S96.
184. Wong PH, White KM. Impact of immunoglobulin therapy in pediatric disease: a review of immune mechanisms. Clin Rev Allergy Immunol 2015 (in press).
185. Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol 1998; 13: 79–82.
186. Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic char-acteristics. J Autism Dev Disord 1996; 26: 439–452.
187. Giudice-Asch G, Simon L, Schmeidler J, Cunningham-Rundles C, Hollander E. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord 1999; 29: 157–160.
188. Melamed I, Gupta S, Bobbitt MS, Gilanders K, Hyland N, Moy JN. Efficacy and Safety of Gammaplex® 5% in Children and AdolescentsAnchor with Primary Immuno-deficiency Diseases. IgNS Annual Conference Proceedings, 2015, 228–36.
189. Heuer LS, Rose M, Ashwood P, Van de Water J. Decreased levels of total immunoglobulin in children with autism are not a result of B cell dysfunction. J Neuroimmunol 2012; 251: 94–102.
190. Siniscalco D, Bradstreet JJ, Cirillo A, Antonucci N. The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages. J Neuroinflammation 2014; 11: 78.
191. Singh K, Connors SL, Macklin EA, Smith KD, Fahey JW, Talalay P et al. Sulfor-aphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci USA 2014; 111: 15550–15555.
192. King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L et al. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr 2013; 167: 1045–1052.
193. Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012; 71: 956–961.
194. Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic dis-orders. BMC Psychiatry 2013; 13: 196.
195. Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev 2015; 55: 294–321.
196. Nikoo M, Radnia H, Farokhnia M, Mohammadi MR, Akhondzadeh S. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irrit-ability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clin Neuropharmacol 2015; 38: 11–17.
197. Taliou A, Zintzaras E, Lykouras L, Francis K. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther 2013; 35: 592–602.
198. Theoharides TC, Asadi S, Panagiotidou S. A case series of a luteolin formulation (Neuroprotek®) in children with autism spectrum disorders. Intl J Immunopathol Pharmacol 2012; 25: 317–323.
199. Theoharides TC, Stewart JM, Hatziagelaki E, Kolaitis G. Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Front Neurosci 2015; 9: 225.
200. Middleton EJ, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000; 52: 673–751.
201. Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci USA 2010; 107: 2687–2692.
202. Scattoni ML, Martire A, Cartocci G, Ferrante A, Ricceri L. Reduced social inter-action, behavioural flexibility and BDNF signalling in the BTBR T+ tf/J strain, a mouse model of autism. Behav Brain Res 2013; 251: 35–40.
203. Johnson RA, Lam M, Punzo AM, Li H, Lin BR, Ye K et al. 7,8-dihydroxyflavone exhibits therapeutic efficacy in a mouse model of Rett syndrome. J Appl Physiol 2012; 112: 704–710.
204. Theoharides T, Athanassiou M, Panagiotidou S, Doyle R. Dysregulated brain immunity and neurotrophin signaling in Rett syndrome and autism spectrum disorders. J Neuroimmunol 2015; 279: 33–38.
205. Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 2000; 30: 501–508.
206. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 2005; 145: 934–944.
207. Weng Z, Patel A, Panagiotidou S, Theoharidess TC. The novel flavone tetra-methoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol 2014; 14: 1044–1052.
208. Dirscherl K, Karlstetter M, Ebert S, Kraus D, Hlawatsch J, Walczak Y et al. Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J Neuroinflammation 2010; 7: 3.
209. Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA 2008; 105: 7534–7539.
210. Chen HQ, Jin ZY, Wang XJ, Xu XM, Deng L, Zhao JW. Luteolin protects dopa-minergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci Lett 2008; 448: 175–179.
211. Parker-Athill E, Luo D, Bailey A, Giunta B, Tian J, Shytle RD et al. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol 2009; 217: 20–27.
212. Harwood M, nielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007; 45: 2179–2205.
213. Theoharides TC, Conti P, Economu M. Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin. J Clin Psychopharmacol 2014; 34: 187–189.
214. Jones QR, Warford J, Rupasinghe HP, Robertson GS. Target-based selection of flavonoids for neurodegenerative disorders. Trends Pharmacol Sci 2012; 33: 602–610.